Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Enhanced de novo lipogenesis mediated by sterol regulatory element-binding proteins (SREBPs) is thought to be involved in nonalcoholic steatohepatitis (NASH) pathogenesis. In this study, we assessed the impact of SREBP inhibition on NASH and liver cancer development in murine models. Unexpectedly, SREBP inhibition via deletion of the SREBP cleavage-activating protein (SCAP) in the liver exacerbated liver injury, fibrosis, and carcinogenesis despite markedly reduced hepatic steatosis. These phenotypes were ameliorated by restoring SREBP function. Transcriptome and lipidome analyses revealed that SCAP/SREBP pathway inhibition altered the fatty acid (FA) composition of phosphatidylcholines due to both impaired FA synthesis and disorganized FA incorporation into phosphatidylcholine via lysophosphatidylcholine acyltransferase 3 (LPCAT3) downregulation, which led to endoplasmic reticulum (ER) stress and hepatocyte injury. Supplementation with phosphatidylcholines significantly improved liver injury and ER stress induced by SCAP deletion. The activity of the SCAP/SREBP/LPCAT3 axis was found to be inversely associated with liver fibrosis severity in human NASH. SREBP inhibition also cooperated with impaired autophagy to trigger liver injury. Thus, excessively strong and broad lipogenesis inhibition was counterproductive for NASH therapy; this will have important clinical implications in NASH treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice
Hara, T., Nakamura, K., Matsui, M., Yamamoto, A., Nakahara, Y., Suzuki-Migishima, R., Yokoyama, M., Mishima, K., Saito, I., Okano, H., et al. (2006) · Nature · doi:10.1038/nature04724 · Cited by 3,882 · cited 1×
“Toronto, Toronto, Canada) and Noboru Mizushima (University of Tokyo, Tokyo, Japan), respectively (55, 56).”
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“Although lipid influx to the liver from insulin-resistant adipose tissue and dietary fat is increased in patients with NASH, hepatic de novo lipogenesis is paradoxically enhanced (2, 3).”
BackgroundObesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
Autophagy Is Activated for Cell Survival after Endoplasmic ReticulumStress
Ogata, M., Hino, S.-I., Saito, A., Morikawa, K., Kondo, S., Kanemoto, S., Murakami, T., Taniguchi, M., Tanii, I., Yoshinaga, K., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01453-06 · Cited by 1,832
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338 · cited 1×
“(50) analyzed the lipid composition of liver biopsy specimens and found that total PC amounts were decreased in patients with NAFLD and NASH compared with healthy subjects and that PCs containing C20:4 were particularly decreased in NASH patients.”
BackgroundLipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
Vilar-Gomez, E., Calzadilla-Bertot, L., Wai-Sun Wong, V., Castellanos, M., Aller-de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Alvarez-Quiñones Sanz, M., Conde-Martin, A. F., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.034 · Cited by 806
Liang, G., Yang, J., Horton, J. D., Hammer, R. E., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111421200 · Cited by 669
ER Stress Cooperates with Hypernutrition to Trigger TNF-Dependent Spontaneous HCC Development
Nakagawa, H., Umemura, A., Taniguchi, K., Font-Burgada, J., Dhar, D., Ogata, H., Zhong, Z., Valasek, M. A., Seki, E., Hidalgo, J., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.001 · Cited by 525 · cited 3×
“Prebys Medical Discovery Institute, La Jolla, California, USA) (6).”
BackgroundSelf-citationPast, present and future perspectives in nonalcoholic fatty liver disease
Sanyal, A. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0144-8 · Cited by 522 · cited 1×
“Based on these concepts, several drugs targeting enzymes involved in hepatic de novo lipogenesis, such as acetyl-CoA carboxylase (ACC), FA synthase (FASN), and stearoyl-CoA desaturase 1 (SCD1), are under development (7, 8).”
BackgroundSystematic evaluation of spliced alignment programs for RNA-seq data
The RGASP Consortium, Engström, P. G., Steijger, T., Sipos, B., Grant, G. R., Kahles, A., Rätsch, G., Goldman, N., Hubbard, T. J., Harrow, J., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2722 · Cited by 513 · cited 1×
“algorithm (58), and gene expression levels were normalized using the”
MethodGovaere, O., Cockell, S., Tiniakos, D., Queen, R., Younes, R., Vacca, M., Alexander, L., Ravaioli, F., Palmer, J., Petta, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4448 · Cited by 479
ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P
Kim, J. Y., Garcia-Carbonell, R., Yamachika, S., Zhao, P., Dhar, D., Loomba, R., Kaufman, R. J., Saltiel, A. R., & Karin, M. (2018) · Cell · doi:10.1016/j.cell.2018.08.020 · Cited by 333 · cited 1×
“Caspase-2 is an alternative pathway to activating SREBP in NASH (21).”
BackgroundMusso, G., Cassader, M., Paschetta, E., & Gambino, R. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.031 · Cited by 332
Rong, S., Cortés, V. A., Rashid, S., Anderson, N. N., McDonald, J. G., Liang, G., Moon, Y.-A., Hammer, R. E., & Horton, J. D. (2017) · eLife · doi:10.7554/elife.25015 · Cited by 134
Cell fate analysis of zone 3 hepatocytes in liver injury and tumorigenesis
Kurosaki, S., Nakagawa, H., Hayata, Y., Kawamura, S., Matsushita, Y., Yamada, T., Uchino, K., Hayakawa, Y., Suzuki, N., Hata, M., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100315 · Cited by 34
Self-citation
Cited by
ROS/RNS as molecular signatures of chronic liver diseases
Che, Z., Zhou, Z., Li, S.-Q., Gao, L., Xiao, J., & Wong, N.-K. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.08.001 · Cited by 110
Autophagy and senescence: the molecular mechanisms and implications in liver diseases
Li, Q., Lin, Y., Liang, G., Xiao, N., Zhang, H., Yang, X., Yang, J., & Liu, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316880 · Cited by 43
“SREBP cleavage-activating proteins (SCAP) are also involved in the pathogenesis of NASH [73].”
BackgroundZhang, F., Gao, J., Liu, X., Sun, Y., Liu, L., Hu, B., Wang, Z., Shi, J., Guo, W., & Zhang, S. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23538 · Cited by 12
“However, a recent study revealed that loss of SREBP2 could induce hepatocarcinogenesis.(36) Thus, further investigation of the role and associated mechanism of SREBP2 in HCC was necessary.”
Background
Metadata
- Authors
- Kawamura, S., Matsushita, Y., Kurosaki, S., Tange, M., Fujiwara, N., Hayata, Y., Hayakawa, Y., Suzuki, N., Hata, M., Tsuboi, M., Kishikawa, T., Kinoshita, H., Nakatsuka, T., Sato, M., Kudo, Y., Hoshida, Y., Umemura, A., Eguchi, A., Ikenoue, T., Hirata, Y., Uesugi, M., Tateishi, R., Tateishi, K., Fujishiro, M., Koike, K., & Nakagawa, H.
- Venue
- Journal of Clinical Investigation
- Published
- 2022-06-01
- Volume
- 132
- Issue
- 11
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W4226154198
- Cited by
- 115
- References
- 18
- FWCI
- 14.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.